Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 279

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 279
---
 goals and objectives; •retaining and approving the compensation of any compensation advisors; •reviewing all equity -compensationplans to be submitted for shareholder approval under the NASDAQ listing rules, and reviewing and approving all equity -compensationplans that are exempt from such shareholder approval requirement; •evaluating the appropriate level of compensation for board and board committee service by non -employeedirectors; and •reviewing and approving description of executive compensation included in our Annual Report on Form 20 -F. Nominating and Corporate Governance Committee Douglas Arner (chair) and Justin Wu currently serve on the nominating and corporate governance committee, which is chaired by Professor Arner. Our Board of Directors has determined that each member of the nominating and corporate governance committee is “independent” as that term is defined in the applicable rules of the Nasdaq Capital Market. The nominating and corporate governance committee’s responsibilities include: •assisting our Board of Directors in identifying prospective director nominees and recommending nominees for election by the shareholders or appointment by our Board of Directors; •advising the board of directors periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our Board of Directors on all matters of corporate governance and on any corrective action to be taken; •overseeing the evaluation of our Board of Directors; and •recommending members for each board committee of our Board of Directors. 158 Scientific Advisory Board We restructured the Scientific Assessment Committee into a Scientific Advisory Board. The Scientific Advisory Board shall help the Company sharpen its focus on innovation and technological advancements and address critical scientific challenges in our research and development; it will provide overall advise on the scientific development of the company. As of the date of this proxy statement/prospectus, we have 29 members on this board. In light of the Company’s focus on developing treatment for infectious diseases, we have established a second scientific advisory board, i.e., the Infectious Diseases Scientific Advisory Board in April 2020. As of the date hereof, the Infectious Diseases Scientific Advisory Board has 4 members. Code of Business Conduct and Ethics Our board has adopted a code of business conduct and ethics that applies to our directors, officers and employees. A copy of this code is available on our website: www.aptorumgroup.com. We intend to disclose on our website or in a current report on Form 6 -K, any amendments to the Code of Business Conduct and Ethics and any waivers of the